glycolytic profile that are thought to be responsible of the resistance of GBM to treatments. Metabolic reprogramming allows tumor cells to survive in unsupported microenvironments. Manipulating tumor metabolism to counteract GBM resistance arises as a powerful approach with minimum effects in normal counterparts. At pharmacological concentrations, melatonin displays oncostatic properties. This is thought to be due to an increase in mitochondrial oxidative phosphorylation through the effects of melatonin in mitocondria, where it organizes fatty acids into mitochondrial fatty acid synthase. We hypothesize that melatonin could alter BFC metabolism, by inducing an anti-Warburg effect and as consequence, melatonin will decrease the viability of GBM cells and tumor growth. We found that treatment of GBM cell lines with 3mM melatonin significantly altered their cell metabolism. We observed that melatonin downregulated the lactate synthase MCT4 (p<0.002), inducing a significant intracellular accumulation of lactate (p<0.002) while decreasing it in the extracellular media (p<0.001). This was followed by a decrease in the internal pH (p<0.002). These effects were compensated by an increase in the oxygen consumption rate (OCR) followed by decay that led to an increase in ROS production (p<0.001). All these changes result in a depletion of cellular ATP (p<0.001) and eventually drove to a decrease in the proliferaton (p<0.001) and cell death (p<0.001). When applied in vivo we observed a significant reduction in the tumor growth (p<0.001), volume (p<0.002) and weight (p<0.002), as well as a drop in the proliferation marker ki67 (p<0.001) and a fibrosis increase in treated tumors. These results position melatonin as a strong therapeutic candidate for GBM therapy.

SULFIDE SUPPRESSION IN GBM

The gasotransmitter hydrogen sulfide (H₂S) is an endogenously produced bio-active metabolite derived from sulfur amino acid catabolism. It functions principally through protein S-sulfhydration and regulates a variety of programs including mitochondrial bioenergetics and cellular metabolism. Inhibition of H₂S synthesis resulted in increased proliferation and chemoresistance, whereas treatment with H₂S donors led to cytotoxicity and death of cultured GBM cells. Compared to non-cancerous controls, patient GBM specimens were reduced in overall protein S-sulfhydration, which was primarily lost from proteins regulating cellular metabolism. These findings support the hypothesis that diet-regulated H₂S signaling serves to suppress GBM by restricting metabolic adaptability, while its loss triggers CSC enrichment and disease acceleration. Interventions augmenting H₂S bioavailability concurrent with GBM standard of care may improve outcomes for GBM patients.

LIMITING IRON IN LEPTOMENINGEAL METASTASIS

Iron chelation therapy. A Phase Ia/Ib clinical trial focused on this novel treatment for GBM patients.

BITHI AHUJA MEIMAN

DDRE-34. TARGETING RESISTANCE IN MEDULLOBLASTOMA

Simone Chang, Evan Meiman, Sucheta Telang, University of Louisville, Louisville, KY, USA

Medulloblastoma is the most commonly diagnosed pediatric brain tumor. Although therapeutic advances have improved survival from this cancer, they result in devastating sequelae and, additionally, have proven inadequate in preventing or arresting disease recurrence. Active therapies are urgently needed to improve outcomes in medulloblastoma. Medulloblastoma development is driven by dysregulation of normal cerebellar proliferation. Mutations in the sonic hedgehog (Shh) pathway are strongly induced PFKFB4 expression in Shh-driven medulloblastoma cells and that silencing PFKFB4 suppressed F26BP, Ras/MAPK and HIF-1α, indicating that hypoxia, through HIF-1α, strongly induced PFKFB4 expression in Shh-driven medulloblastoma cells and that silencing PFKFB4 suppressed F26BP, Ras/MAPK and HIF-1α. This is supported in vitro and in vivo by the observation of increased proliferation and chemoresistance in tumors bearing mice fed an obesity-inducing high-fat diet (HFD) versus an energy-balanced, low-fat control diet. HFD consumption resulted in hyper-aggressive disease that was accompanied by CSC enrichment and shortened survival. HFD consumption also drove intracerebral accumulation of saturated fats, which in turn inhibited the production and signaling of the gasotransmitter hydrogen sulfide (H₂S), H₂S is an endogenously produced bio-active metabolite derived from sulfur amino acid catabolism. It functions principally through protein S-sulfhydration and regulates a variety of programs including mitochondrial bioenergetics and cellular metabolism. Inhibition of H₂S synthesis resulted in increased proliferation and chemoresistance, whereas treatment with H₂S donors led to cytotoxicity and death of cultured GBM cells. Compared to non-cancerous controls, patient GBM specimens were reduced in overall protein S-sulfhydration, which was primarily lost from proteins regulating cellular metabolism. These findings support the hypothesis that diet-regulated H₂S signaling serves to suppress GBM by restricting metabolic adaptability, while its loss triggers CSC enrichment and disease acceleration. Interventions augmenting H₂S bioavailability concurrent with GBM standard of care may improve outcomes for GBM patients.

ETMM-02. PRECLINICAL MODELS REVEAL BRAIN-MICROENVIRONMENT SPECIFIC METABOLIC DEPENDENCIES IN GliOBLASTOMA

Jenna Minami, Nicholas Bayley, Christopher Tse, Henan Zhu, Danielle Morrow, William Yong, Linda Liu, Timothy F Cloughesy, Thomas Graebel, David A Nathanson; UCLA, Los Angeles, CA, USA

Metabolic reprogramming is a hallmark of cancer, and malignant cells must acquire metabolic adaptations in response to a multitude of intrinsic and extrinsic factors to fuel neoplastic progression. Mutations or changes in metabolic gene expression can impose nutrient dependencies in tumors, and even in the absence of metabolic defects, cancer cells can become autotrophic for particular nutrients or metabolic byproducts generated by other cells in the tumor microenvironment (TME). Conventional cell culture models do not recapitulate the metabolic heterogeneity of glioblastoma (GBM), while primary cultured cells do not account for the influences of the microenvironment and the blood brain barrier on tumor biology. Additionally, these systems are under strong selective pressure divergent from that in vivo, leading to reduced heterogeneity between cultured tumor cells. Here, we describe a biobank of direct-from-patient derived orthotopic xenografts (GliomaPDOX) and gliospheres that reveal a subset of gliomas that while able to form in vivo, cannot survive in vitro. RNA sequencing of tumors that can form both in vivo and in vitro (termed “TME-Indifferent”) compared to that of tumors that can only form in vivo (“TME-Dependent”) revealed transcriptional changes associated with altered nutrient availability, emphasizing the unique metabolic programs impacted by the tumor microenvironment. Furthermore, TME-dependent tumors lack metabolic signatures associated with nutrient biosynthesis, thus indicating a potential dependence of these tumors on scavenging specific nutrients from the extracellular milieu. Collectively, these data indicate heterogeneity within glioblastoma (GBM) and reveal a subset of gliomas that lack metabolic plasticity, indicating a potential brain-microenvironment specific metabolic dependency that can be targeted for therapy.

ETMM-03. CANCER CELLS DEPLOY LIPOCALIN-2 TO COLLECT LIMITING IRON IN LEPTOMENINGEAL METASTASIS

Yudan Chi1, Jan Rensvik2, Vadiodas Kiselova3, Camille Derderian1, Ugur Sener1, Majdi Alghadeer2, Fadi Saddeh1, Kate Nikishina1, Tejus Bale1, Christin Iacobuzo-Donahue1, Tiffany Thomas1, Dana Pe'er2, Linas Mazutis1, Adrienne Bour31, MSKCC, New York, NY, USA, 2CUNY, New York, NY, USA, 3Columbia University, New York, New York, USA

The tumor microenvironment plays a critical regulatory role in cancer progression, especially in central nervous system metastases. Cancer cells within the cerebrospinal fluid (CSF)-filled leptomeninges face substantial metabolic and environmental challenges including inflammation and nutrient micro-nutrients. To investigate the mechanism by which cancer cells in these leptomeningeal metastases (LM) overcome these constraints, we subjected CSF from five patients with LM to single-cell RNA sequencing. We found that cancer cells do not macrophores cytokines, but instead use the CSF expression of protein lipocalin-2 (LCN2) and its receptor SCL22A17. These macrophages generate inflammatory cytokines that induce cancer cell LCN2 expression but do not generate LCN2 themselves. In mouse models of LM, cancer cells are protected by the LCN2/SLC22A17 system and is inhibited by iron chelation therapy. A Phase Ia/ Ib clinical trial focused on this novel treatment approach is underway.

EPIDENOME, TRANSCRIPTOME, METABOLOME AND MODELING

ETMM-01. CANCER STEM CELL ENRICHMENT AND METABOLIC SUBSTRATE ADAPTABILITY ARE DRIVEN BY HYDROGEN SULFIDE SUPPRESSION IN GliOBLASTOMA

Daniel I. Silver1,2, Gustavo A. Roversi1, Nazmin Bithi1, Chase K. A. Neumann3, Katie M. Troike1, Grace K. Ahuja4,1, Ofer Reizes1,2, J. Mark Brown1,2, Christopher Hine1,2, Justin D. Latha1,2,1, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA, 2Case Comprehensive Cancer Center, Cleveland, OH, USA

Glioblastoma (GBM) remains among the deadliest of human malignant cancers. Since the cancer stem cell (CSC) phenotype was first proposed as a major challenge to disease management and durable treatment response. The extrinsic, environmental, and lifestyle factors that result in CSC enrich-ment are not well understood. The CSC state endows cells with a fluid metabolic profile, enabling the utilization of multiple nutrient sources. Therefore, to test the impact of diet on CSC enrichment, we evaluated disease progression in tumor-bearing mice fed an obesity-inducing high-fat diet (HFD) versus an energy-balanced, low-fat control diet. HFD consumption resulted in hyper-aggressive disease that was accompanied by CSC enrichment and shortened survival. HFD consumption also drove intracerebral accumulation of saturated fats, which in turn inhibited the production and signaling of the gasotransmitter hydrogen sulfide (H₂S). H₂S is an endogenously produced bio-active metabolite derived from sulfur amino acid catabolism. It functions principally through protein S-sulfhydration and regulates a variety of programs including mitochondrial bioenergetics and cellular metabolism. Inhibition of H₂S synthesis resulted in increased proliferation and chemoresistance, whereas treatment with H₂S donors led to cytotoxicity and death of cultured GBM cells. Compared to non-cancerous controls, patient GBM specimens were reduced in overall protein S-sulfhydration, which was primarily lost from proteins regulating cellular metabolism. These findings support the hypothesis that diet-regulated H₂S signaling serves to suppress GBM by restricting metabolic adaptability, while its loss triggers CSC enrichment and disease acceleration. Interventions augmenting H₂S bioavailability concurrent with GBM standard of care may improve outcomes for GBM patients.

Glioblastoma (GBM) remains among the deadliest of human malignant cancers. Since the cancer stem cell (CSC) phenotype was first proposed as a major challenge to disease management and durable treatment response. The extrinsic, environmental, and lifestyle factors that result in CSC enrich-ment are not well understood. The CSC state endows cells with a fluid metabolic profile, enabling the utilization of multiple nutrient sources. Therefore, to test the impact of diet on CSC enrichment, we evaluated disease progression in tumor-bearing mice fed an obesity-inducing high-fat diet (HFD) versus an energy-balanced, low-fat control diet. HFD consumption resulted in hyper-aggressive disease that was accompanied by CSC enrichment and shortened survival. HFD consumption also drove intracerebral accumulation of saturated fats, which in turn inhibited the production and signaling of the gasotransmitter hydrogen sulfide (H₂S). H₂S is an endogenously produced bio-active metabolite derived from sulfur amino acid catabolism. It functions principally through protein S-sulfhydration and regulates a variety of programs including mitochondrial bioenergetics and cellular metabolism. Inhibition of H₂S synthesis resulted in increased proliferation and chemoresistance, whereas treatment with H₂S donors led to cytotoxicity and death of cultured GBM cells. Compared to non-cancerous controls, patient GBM specimens were reduced in overall protein S-sulfhydration, which was primarily lost from proteins regulating cellular metabolism. These findings support the hypothesis that diet-regulated H₂S signaling serves to suppress GBM by restricting metabolic adaptability, while its loss triggers CSC enrichment and disease acceleration. Interventions augmenting H₂S bioavailability concurrent with GBM standard of care may improve outcomes for GBM patients.

Abstracts